The unchanged GPx levels observed in all the groups with PCOS and only slightly reduced GR in the groups with increased risk of metabolic disorders may be the result of a compensatory antioxidant response associated with the activation of the Keap1-Nrf2 system. The gene discussed is NFE2L2; the disease is polycystic ovary syndrome.